New Technologies/ view all

  • Transgenic animals to produce therapeutic proteins

    Biosidus has concluded is working on novel technologies for high-yield and cost-effective production of recombinant proteins for pharmaceutical applications.

  • Gene Therapy

    Angiogenesis and muscle regeneration using the vascular endothelial growth factor.
    Vascular endothelial growth factor (VEGF) is a protein that stimulates the growth of blood vessels.

  • Biodiversity

    White Genome Project
    Yet another groundbreaking initiative for Biosidus is the White Genome Project, which aims to isolate, identify and characterize Antarctic bacterial strains for further sequencing of the complete genome.


Pipeline | developing products

PEG-interferon alfa 2a The conjugation of therapeutic proteins with polyethylene glycol (PEG) improves their pharmacological properties when compared to the native forms. Pegylated proteins present a decrease in both proteolytic degradation and kidney clearance, resulting in an increased blood half-life. The linking of PEG to Interferon alfa 2a (PEG-Interferon) confers to the derivative molecule a longer permanence in the blood stream, thus allowing for a prolonged antiviral action in a once weekly dosing scheme. This therapy enhances patient compliance to treatment due to a more comfortable administration schedule. procedimiento terapéutico.

PEG-filgrastim Filgrastim, the active ingredient ot Biosidus Neutromax® is used in the treatment of neutropenia induced by cytotoxic drugs and during transplantation of hematopoietic precursors. The recommended dosing scheme is one daily dose for five consecutive days. A single dose of pegylated filgrastim (a derivative of filgrastim, called pegfilgrastim) achieves therapeutic activity for a week, thus resulting in more comfort to patients and better adhesion to treatment.

Agalsidase beta (alpha galactosidase) and imiglucerase. Agalsidase beta (alpha galactosidase) and imiglucerase are enzymes used to treat congenital deficiencies of lysosomal enzymes involved in metabolism. Patients suffering this condition are unable to metabolize and breakdown certain types of fats, which may be toxic (sphingolipids), resulting in a buildup of fatty material in the spleen, liver, kidneys, lungs, brain and bone marrow. Deficiencies of the endogenous lysosomal enzyme alpha-galactosidase A or alpha-GAL lead to Fabry’s disease, an inherited disorder. Agalsidase beta is a human recombinant enzyme used to treat patients suffering from Fabry’s disease.
Likewise, deficiencies of the endogenous lysosomal enzyme glucocerebrosidase lead to Gaucher’s disease. Imiglucerase is the recombinant human version of beta glucocerebrosidase used to treat patients suffering from Gaucher’s disease.